Royal Bank of Canada
VRDN icon

Royal Bank of Canada’s Viridian Therapeutics VRDN Stock Holding History

Royal Bank of Canada’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121K Buy
6,218
+187
+3% +$5.55K ﹤0.01% 5018
2025
Q4 		$188K Sell
6,031
-362,570
-98% -$9.94M ﹤0.01% 4812
2025
Q3 		$7.96M Buy
368,601
+22,703
+7% +$409K ﹤0.01% 2307
2025
Q2 		$4.83M Buy
345,898
+345,685
+162,293% +$4.69M ﹤0.01% 2593
2025
Q1 		$3K Sell
213
-3,436
-94% -$58.5K ﹤0.01% 6533
2024
Q4 		$70K Sell
3,649
-2,772
-43% -$60.3K ﹤0.01% 5519
2024
Q3 		$146K Buy
6,421
+236
+4% +$3.86K ﹤0.01% 5068
2024
Q2 		$81K Buy
6,185
+4,399
+246% +$60.9K ﹤0.01% 5395
2024
Q1 		$32K Sell
1,786
-11,324
-86% -$220K ﹤0.01% 5719
2023
Q4 		$286K Buy
13,110
+7,242
+123% +$114K ﹤0.01% 4772
2023
Q3 		$90K Buy
5,868
+2,669
+83% +$50.9K ﹤0.01% 5450
2023
Q2 		$76K Buy
3,199
+1,049
+49% +$26.9K ﹤0.01% 5537
2023
Q1 		$54K Sell
2,150
-2,123
-50% -$68.1K ﹤0.01% 5586
2022
Q4 		$124K Buy
4,273
+3,950
+1,223% +$91K ﹤0.01% 5291
2022
Q3 		$7K Buy
323
+177
+121% +$3.18K ﹤0.01% 6618
2022
Q2 		$2K Sell
146
-6,791
-98% -$91.3K ﹤0.01% 7005
2022
Q1 		$128K Buy
+6,937
New +$133K ﹤0.01% 5469
2020
Q4 		– Hold
0
– – – 7314
2020
Q3 		– Sell
-52
Closed -$775 – 6956
2020
Q2 		$1K Hold
52
– – ﹤0.01% 6490
2020
Q1 		$0 Buy
+52
New +$605 ﹤0.01% 7060
2019
Q4 		– Sell
-2
Closed – – 7146
2019
Q3 		$0 Buy
+2
New +$44 ﹤0.01% 7160
2018
Q4 		– Sell
-40
Closed -$3K – 7145
2018
Q3 		$3K Buy
40
+24
+150% +$2.26K ﹤0.01% 6445
2018
Q2 		$2K Buy
16
+9
+129% +$952 ﹤0.01% 6275
2018
Q1 		$1K Hold
7
– – ﹤0.01% 6232
2017
Q4 		$1K Sell
7
-66
-90% -$8.41K ﹤0.01% 6430
2017
Q3 		$10K Buy
73
+72
+7,200% +$12.1K ﹤0.01% 6274
2017
Q2 		$0 Buy
+1
New +$169 ﹤0.01% 6784

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Royal Bank of Canada's VRDN Position: Q1 2026 in Review

Royal Bank of Canada increased its Viridian Therapeutics (VRDN) stake by 3.1% in Q1 2026, buying an estimated $5.55K and bringing the position to 6,218 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #5018.

Royal Bank of Canada first reported a position in VRDN in Q2 2017 and has held it in 26 quarters since. The position peaked at $7.96M in Q3 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Royal Bank of Canada held 6,218 shares of Viridian Therapeutics worth $121K as of Q1 2026.
  • Royal Bank of Canada bought 187 Viridian Therapeutics shares in Q1 2026, an estimated $5.55K.
  • Viridian Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5018 holding.
  • Royal Bank of Canada first reported a position in Viridian Therapeutics in Q2 2017 and has held it in 26 quarters since.
  • Royal Bank of Canada's Viridian Therapeutics position peaked at $7.96M in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.